WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2563
[post_author] => 3
[post_date] => 2017-01-12 19:50:10
[post_date_gmt] => 2017-01-12 19:50:10
[post_content] => 
New York City based start-up Celmatix has unveiled “Fertilome”, a DNA-based fertility test. The company describes Fertilome as the “first genetic screen that examines a woman’s genetic signature and how it may impact her reproductive health and ability to conceive, today and in the future.”
Fertilome looks at 49 variants in 32 genes associated with a broad spectrum of female reproductive conditions. Information derived from the test could allow women to see a broader picture of their fertility, allowing for a more proactive approach to planning their family and overcoming fertility issues. Click here to read more about Celmatix and Fertilome.
[post_title] => Celmatix unveils Fertilome
[post_excerpt] => New York City based start-up Celmatix has unveiled “Fertilome”, a DNA-based fertility test.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => celmatix-unveils-fertilome
[to_ping] =>
[pinged] =>
[post_modified] => 2017-02-28 14:29:44
[post_modified_gmt] => 2017-02-28 14:29:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2563
[menu_order] => 154
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3592
[post_author] => 3
[post_date] => 2020-07-24 11:40:47
[post_date_gmt] => 2020-07-24 11:40:47
[post_content] => The RADx Tech initiative aims to speed the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improve clinical laboratory tests, that can directly detect the virus. RADx Tech will expand the Point-of-Care Technologies Research Network (POCTRN) established several years ago by NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB).
All scientists and inventors with a rapid testing technology are invited to compete in a national “shark tank”-type COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will go through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. Finalists will be matched with technical, business, and manufacturing experts to increase the odds of success.
Applications will be accepted on a rolling basis. Visit program website for full details on the RADx Programs and application process. https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs
[post_title] => Update: NIH Rapid Acceleration of Diagnostics (RADx) Programs
[post_excerpt] => Scientists and inventors with a COVID-19 rapid testing technology: RADx Tech initiative challenge awarding shares of up to $500 million over all phases of development.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => update-nih-rapid-acceleration-of-diagnostics-radx-programs
[to_ping] =>
[pinged] =>
[post_modified] => 2020-07-24 11:40:47
[post_modified_gmt] => 2020-07-24 11:40:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3592
[menu_order] => 59
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2997
[post_author] => 4
[post_date] => 2018-07-02 19:00:11
[post_date_gmt] => 2018-07-02 19:00:11
[post_content] => Former Pfizer Senior Scientist and Scout Anton Xavier has joined the Center for Biotechnology in the role of Assistant Director of Technology and Business Development. Within this role at the Center, Anton will focus on the development and implementation of technology and business development strategies that will increase sponsored research, company formation, strategic alliances, and investment with external partners. Anton will also provide oversight to the Center’s Commercialization Associates offering technology / business development services and education to entrepreneurial faculty and emerging companies.
During his tenure at Pfizer, Anton had duties within the External Science and Innovation group (ES&I) focusing on sourcing, screening, and evaluating early through to late stage (inter)national biopharma ventures, entrepreneurial academic PI technology, private/public/local government funded life science initiatives, and funding vehicles which aligned with Pfizer’s R&D interest for investment and strategic partnerships. Additionally, Anton led efforts within Pfizer R&D from discovery through to late stage development of targeted therapeutics for oncology indications.
Prior to Pfizer, Anton’s experience was within a wider field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs.
Anton is currently a mentor and adjunct faculty member for early stage life science ventures with E-Lab NYC, ABCT (Accelerator for Biosciences in Connecticut), NSF’s I-Corps program, the British Consulate NYC, Business France, and Cornell / Columbia University, where he provides critical industry based science, strategy, and business development input for bio-venture development.
Anton earned a Master’s degree in Business Administration (MBA) from Cornell University’s Johnson Graduate School of Management, a Master of Science (MSc) in Toxicology from Imperial College London and a Bachelor of Science in Biochemistry with Microbiology from Queen Mary University of London.
Anton can be reached at the Center for Biotechnology by emailing anton.xavier@stonybrook.edu
[post_title] => Anton Xavier Joins CFB in Technology and Business Development Role
[post_excerpt] => Former Pfizer Senior Scientist and Scout will focus on the development and implementation of technology and business development strategies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => anton-xavier-joins-cfb-in-technology-and-business-development-role
[to_ping] =>
[pinged] =>
[post_modified] => 2018-07-02 19:00:40
[post_modified_gmt] => 2018-07-02 19:00:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2997
[menu_order] => 120
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 261
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
